Clinical trial
Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and…
NCT00094146 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00094146 |
|---|---|
| Title | Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Insulin Hypersecretion, Obesity |
| Intervention type | Drug |
| Interventions | Sandostatin LAR Depot |
| Enrollment | 160 |
| Start date | Jan 1, 2002 |
| Completion | Dec 1, 2002 |
| First posted | Oct 15, 2004 |
| Last update posted | Sep 22, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: